Trial Outcomes & Findings for ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance (NCT NCT04895085)

Results Overview

Feasibility of home based COVID-19 testing will be evaluated by protocol uptake. Data will be retrieved from the study log.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

51 participants

Primary outcome timeframe

Study duration (up to 21 months)

Results posted on

2024-06-07

Participant Flow

The protocol enrollment, started, and completed values reflect caregiver/child dyads. All dyads assigned to the intervention had one caregiver to one child (n = 51 caregivers, n = 51 children). All participants were assigned to the intervention group.

Participant milestones

Participant milestones
Measure	Caregiver of Children With Medical Complexity (CMC) BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Overall Study STARTED	51
Overall Study COMPLETED	48
Overall Study NOT COMPLETED	3

Reasons for withdrawal

Reasons for withdrawal
Measure	Caregiver of Children With Medical Complexity (CMC) BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Overall Study Death	1
Overall Study Withdrawal by Subject	1
Overall Study No longer eligible: Moved from area	1

Baseline Characteristics

ReSET Aim 1a: Restarting Safe Education and Testing for Children With Medical Complexity - Feasibility of In-home Cohort COVID-19 Testing Strategies, and Associations With CMC Parent Perceptions About In-person School Attendance

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.	Child With Medical Complexity n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.	Total n=102 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	51 Participants n=7 Participants	51 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	51 Participants n=5 Participants	0 Participants n=7 Participants	51 Participants n=5 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Age, Continuous	39 years n=5 Participants	9 years n=7 Participants	NA years n=5 Participants
Sex: Female, Male Female	48 Participants n=5 Participants	20 Participants n=7 Participants	68 Participants n=5 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	31 Participants n=7 Participants	34 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants n=5 Participants	6 Participants n=7 Participants	10 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	46 Participants n=5 Participants	44 Participants n=7 Participants	90 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) Asian	2 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) White	46 Participants n=5 Participants	42 Participants n=7 Participants	88 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	4 Participants n=7 Participants	4 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	3 Participants n=5 Participants	2 Participants n=7 Participants	5 Participants n=5 Participants
Region of Enrollment United States	51 Participants n=5 Participants	51 Participants n=7 Participants	102 Participants n=5 Participants

PRIMARY outcome

Timeframe: Study duration (up to 21 months)

Population: The number of participants analyzed must reflect the number of participants approached in addition to those consented.

Feasibility of home based COVID-19 testing will be evaluated by protocol uptake. Data will be retrieved from the study log.

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=84 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Protocol Uptake: Number of Participants Consented Compared to Number of Participants Approached Number approached, consented	51 Caregiver/child dyads
Change in Protocol Uptake: Number of Participants Consented Compared to Number of Participants Approached Number approached, not consented	33 Caregiver/child dyads

PRIMARY outcome

Timeframe: Every week up to 21 months

Feasibility of home based COVID-19 testing will be evaluated by the mean number of weekly in home COVID-19 tests run by parents/caregivers. Data will be collected by survey.

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=3254 BinaxNOW Rapid Antigen COVID-19 Tests BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Mean Number of Weekly in Home COVID-19 Tests	1.8 BinaxNow Antigen COVID-19 Tests per week Standard Deviation 0.3

PRIMARY outcome

Timeframe: Study duration (up to 21 months)

Data will be collected by survey. * Tests expected: Various scenarios factor into the tests expected value. Caregivers were expected to test their child twice a week every week for the first three months. After that time, caregivers could opt-in to surveillance testing (expected testing twice a week every week) or proceed with symptomatic-only testing (no "expected" tests for caregivers). Additionally, caregivers were not expected to test for 90 days after their child tested positive. * Tests completed: Caregivers were allowed to test more often than twice a week if appropriate (e.g., exposure to COVID-19). All symptomatic-only tests were not considered expected tests. These factors allowed the number of tests completed to exceed the number of tests expected.

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=3254 BinaxNOW Rapid Antigen COVID-19 Tests BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in COVID Test Rate at Home: Number of Total Tests Completed as Compared to Number of Tests Expected Number of tests completed	3254 BinaxNOW Rapid Antigen COVID-19 Tests
Change in COVID Test Rate at Home: Number of Total Tests Completed as Compared to Number of Tests Expected Number of tests expected	2572 BinaxNOW Rapid Antigen COVID-19 Tests

PRIMARY outcome

Timeframe: Study duration (up to 21 months)

Data will be collected from parents via survey.

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=3254 BinaxNOW Rapid Antigen COVID-19 Tests BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Symptomatic Test Rate: Number of Symptomatic Tests Completed	729 Symptomatic BinaxNow Rapid Antigen Tests

PRIMARY outcome

Timeframe: Study duration (up to 21 months)

Data will be collected from parents via survey.

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=3254 BinaxNOW Rapid Antigen COVID-19 Tests BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Positive Rate: Number of Positive COVID-19 Tests Compared to Total Number of Tests Performed Number of positive COVID-19 tests	39 BinaxNow Rapid Antigen COVID-19 Tests
Change in Positive Rate: Number of Positive COVID-19 Tests Compared to Total Number of Tests Performed Total number of tests performed	3254 BinaxNow Rapid Antigen COVID-19 Tests

PRIMARY outcome

Timeframe: Study duration (up to 21 months)

Data will be collected from parents via survey.

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=109 COVID-19 PCR Tests BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in False-positive Rate: Number of Negative Confirmatory Polymerase Chain Reaction (PCR) as Compared to Total PCR Run for COVID-19 Testing Number of negative confirmatory PCR tests	1 Polymerase chain reaction for COVID-19
Change in False-positive Rate: Number of Negative Confirmatory Polymerase Chain Reaction (PCR) as Compared to Total PCR Run for COVID-19 Testing Total COVID-19 PCR tests	109 Polymerase chain reaction for COVID-19

PRIMARY outcome

Timeframe: At month 3

Data will be collected from parents via survey. \- Caregivers were expected to test their child twice a week every week for the first three months. After that time, caregivers could opt-in to surveillance testing (expected testing twice a week every week) or proceed with symptomatic-only testing (no "expected" tests for caregivers).

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Surveillance Opt in: Number of Participants Opting Into Surveillance Compared to Total Number of Enrolled Participants Participants opting into surveillance testing	32 Participants
Surveillance Opt in: Number of Participants Opting Into Surveillance Compared to Total Number of Enrolled Participants Participants not opting into surveillance testing	19 Participants

PRIMARY outcome

Timeframe: baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

"How many of the people who interact with your child at school have been fully vaccinated?" Response options: "None", "A few", "Some" "Most", "All", "Don't Know" Dichotomized into: ("Most" or "All") vs. ("None", "A few", "Some", "Don't Know)

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 9-month · "None", "A few", "Some", "Don't Know"	35 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 15-month · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	16 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 15-month · "None", "A few", "Some", "Don't Know"	23 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School Baseline · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	12 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School Baseline · "None", "A few", "Some", "Don't Know"	39 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 3-month · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	9 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 3-month · "None", "A few", "Some", "Don't Know"	39 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 6-month · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	12 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 6-month · "None", "A few", "Some", "Don't Know"	34 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 9-month · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	10 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 18-month · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	15 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 18-month · "None", "A few", "Some", "Don't Know"	24 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 21-month · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	15 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 21-month · "None", "A few", "Some", "Don't Know"	26 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 24-month · "Most" or "All" of the people who interact with their child at school have been fully vaccinated	17 Participants
Change in Susceptibility: Number of Fully Vaccinated People Who Interact With Participant's Child at School 24-month · "None", "A few", "Some", "Don't Know"	27 Participants

PRIMARY outcome

Timeframe: baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

The following question from the Participant's perceived susceptibility survey will be answered dichotomously and presented qualitatively: * How comfortable are you with...the ability of your child's school to take all precautions to stop the spread of COVID-19? * Response options: "Not at all", "A little", "Somewhat", "Very", "Extremely" * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Susceptibility: School Takes Precautions Baseline · "Very" or "Extremely" comfortable	24 Participants
Change in Susceptibility: School Takes Precautions Baseline · "Not at all", "A little", or "Somewhat" comfortable	27 Participants
Change in Susceptibility: School Takes Precautions 3 months · "Very" or "Extremely" comfortable	17 Participants
Change in Susceptibility: School Takes Precautions 3 months · "Not at all", "A little", or "Somewhat" comfortable	31 Participants
Change in Susceptibility: School Takes Precautions 6 months · "Very" or "Extremely" comfortable	20 Participants
Change in Susceptibility: School Takes Precautions 6 months · "Not at all", "A little", or "Somewhat" comfortable	26 Participants
Change in Susceptibility: School Takes Precautions 9-12 months · "Very" or "Extremely" comfortable	24 Participants
Change in Susceptibility: School Takes Precautions 9-12 months · "Not at all", "A little", or "Somewhat" comfortable	21 Participants
Change in Susceptibility: School Takes Precautions 15 months · "Very" or "Extremely" comfortable	16 Participants
Change in Susceptibility: School Takes Precautions 15 months · "Not at all", "A little", or "Somewhat" comfortable	23 Participants
Change in Susceptibility: School Takes Precautions 18 months · "Very" or "Extremely" comfortable	16 Participants
Change in Susceptibility: School Takes Precautions 18 months · "Not at all", "A little", or "Somewhat" comfortable	21 Participants
Change in Susceptibility: School Takes Precautions 21 months · "Very" or "Extremely" comfortable	13 Participants
Change in Susceptibility: School Takes Precautions 21 months · "Not at all", "A little", or "Somewhat" comfortable	30 Participants
Change in Susceptibility: School Takes Precautions 24 months · "Very" or "Extremely" comfortable	21 Participants
Change in Susceptibility: School Takes Precautions 24 months · "Not at all", "A little", or "Somewhat" comfortable	24 Participants

PRIMARY outcome

Timeframe: baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Following questions from the Participant's perceived susceptibility survey will be answered dichotomously (agree or disagree) and presented qualitatively. * In your opinion, how likely is your child to get sick with COVID-19 by attending school in-person? * Response options: "Not at all", "A little", "Somewhat", "Very", "Extremely" * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Susceptibility: Likely to Get COVID-19 Baseline · "Very" or "Extremely" likely	22 Participants
Change in Susceptibility: Likely to Get COVID-19 Baseline · "Not at all", "A little", or "Somewhat" likely	29 Participants
Change in Susceptibility: Likely to Get COVID-19 3 months · "Very" or "Extremely" likely	18 Participants
Change in Susceptibility: Likely to Get COVID-19 3 months · "Not at all", "A little", or "Somewhat" likely	30 Participants
Change in Susceptibility: Likely to Get COVID-19 6 months · "Very" or "Extremely" likely	21 Participants
Change in Susceptibility: Likely to Get COVID-19 6 months · "Not at all", "A little", or "Somewhat" likely	24 Participants
Change in Susceptibility: Likely to Get COVID-19 9 months · "Very" or "Extremely" likely	16 Participants
Change in Susceptibility: Likely to Get COVID-19 9 months · "Not at all", "A little", or "Somewhat" likely	28 Participants
Change in Susceptibility: Likely to Get COVID-19 15 months · "Very" or "Extremely" likely	19 Participants
Change in Susceptibility: Likely to Get COVID-19 15 months · "Not at all", "A little", or "Somewhat" likely	20 Participants
Change in Susceptibility: Likely to Get COVID-19 18 months · "Very" or "Extremely" likely	23 Participants
Change in Susceptibility: Likely to Get COVID-19 18 months · "Not at all", "A little", or "Somewhat" likely	16 Participants
Change in Susceptibility: Likely to Get COVID-19 21 months · "Very" or "Extremely" likely	23 Participants
Change in Susceptibility: Likely to Get COVID-19 21 months · "Not at all", "A little", or "Somewhat" likely	19 Participants
Change in Susceptibility: Likely to Get COVID-19 24 months · "Very" or "Extremely" likely	25 Participants
Change in Susceptibility: Likely to Get COVID-19 24 months · "Not at all", "A little", or "Somewhat" likely	20 Participants

PRIMARY outcome

Timeframe: 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived severity construct variables will include: * If your child was sick with COVID-19, how likely would...their health be severely affected * Response options: "Not at all", "A little", "Somewhat", "Very", "Extremely" * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 15 month · "Very" or "Extremely" likely	20 Participants
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 15 month · "Not at all", "A little", or "Somewhat" likely	18 Participants
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 18 month · "Very" or "Extremely" likely	25 Participants
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 18 month · "Not at all", "A little", or "Somewhat" likely	14 Participants
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 21 month · "Very" or "Extremely" likely	29 Participants
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 21 month · "Not at all", "A little", or "Somewhat" likely	14 Participants
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 24 month · "Very" or "Extremely" likely	26 Participants
Change in Percentage of Participants for Perceived Severity Survey Question: Health Severely Affected 24 month · "Not at all", "A little", or "Somewhat" likely	19 Participants

PRIMARY outcome

Timeframe: 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived severity construct variables will be: * "If your child was sick with COVID-19, how likely would...their health be permanently reduced" * Response options: "Not at all", "A little", "Somewhat", "Very", "Extremely" * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 21-month · "Very" or "Extremely" likely	18 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 21-month · "Not at all", "A little", or "Somewhat" likely	25 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 24-month · "Very" or "Extremely" likely	19 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 24-month · "Not at all", "A little", or "Somewhat" likely	26 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 15-month · "Very" or "Extremely" likely	17 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 15-month · "Not at all", "A little", or "Somewhat" likely	21 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 18-month · "Very" or "Extremely" likely	20 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Health Permanently Reduced 18-month · "Not at all", "A little", or "Somewhat" likely	19 Participants

PRIMARY outcome

Timeframe: 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived severity construct variables will be: * "If my child was sick with COVID-19, they would have grave health consequences." * Response options: "Not at all", "A little", "Somewhat", "Very", "Extremely" * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 15 month · "Very" or "Extremely" likely	17 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 15 month · "Not at all", "A little", or "Somewhat" likely	21 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 18 month · "Very" or "Extremely" likely	21 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 18 month · "Not at all", "A little", or "Somewhat" likely	18 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 21 month · "Very" or "Extremely" likely	19 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 21 month · "Not at all", "A little", or "Somewhat" likely	24 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 24 month · "Very" or "Extremely" likely	20 Participants
Change in Percentage of Participants to the Perceived Severity Survey Question: Grave Health Consequences 24 month · "Not at all", "A little", or "Somewhat" likely	24 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Participants will answer the following survey question in quite a bit / a great deal vs not: * "Based on the situation right now, how much do you want your child to attend school in-person at least some of the time?"

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 18 month · "Somewhat," "A little," or "Not at all"	12 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) Baseline · "Quite a bit" or "A great deal"	33 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) Baseline · "Somewhat," "A little," or "Not at all"	18 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 3 month · "Quite a bit" or "A great deal"	29 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 3 month · "Somewhat," "A little," or "Not at all"	19 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 6 month · "Quite a bit" or "A great deal"	29 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 6 month · "Somewhat," "A little," or "Not at all"	17 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 9 month · "Quite a bit" or "A great deal"	35 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 9 month · "Somewhat," "A little," or "Not at all"	10 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 15 month · "Quite a bit" or "A great deal"	28 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 15 month · "Somewhat," "A little," or "Not at all"	11 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 18 month · "Quite a bit" or "A great deal"	27 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 21 month · "Quite a bit" or "A great deal"	33 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 21 month · "Somewhat," "A little," or "Not at all"	9 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 24 month · "Quite a bit" or "A great deal"	35 Participants
Change in Motivation to Attend School (Quite a Bit / A Great Deal vs. Not) 24 month · "Somewhat," "A little," or "Not at all"	10 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively. * How important is attending school in-person to your child's overall health? * Dichotomized into: ("Not at all important", "A little important", "Somewhat important") vs. ("Very important", "Extremely important")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Perceived Benefits to Attend School: Important to Health 3 month · "Very important" or "Extremely important"	29 Participants
Change in Perceived Benefits to Attend School: Important to Health Baseline · "Very important" or "Extremely important"	37 Participants
Change in Perceived Benefits to Attend School: Important to Health Baseline · "Not at all important", "A little important", or "Somewhat important"	14 Participants
Change in Perceived Benefits to Attend School: Important to Health 3 month · "Not at all important", "A little important", or "Somewhat important"	19 Participants
Change in Perceived Benefits to Attend School: Important to Health 6 month · "Very important" or "Extremely important"	31 Participants
Change in Perceived Benefits to Attend School: Important to Health 6 month · "Not at all important", "A little important", or "Somewhat important"	15 Participants
Change in Perceived Benefits to Attend School: Important to Health 9 month · "Very important" or "Extremely important"	34 Participants
Change in Perceived Benefits to Attend School: Important to Health 9 month · "Not at all important", "A little important", or "Somewhat important"	11 Participants
Change in Perceived Benefits to Attend School: Important to Health 15 month · "Very important" or "Extremely important"	29 Participants
Change in Perceived Benefits to Attend School: Important to Health 15 month · "Not at all important", "A little important", or "Somewhat important"	10 Participants
Change in Perceived Benefits to Attend School: Important to Health 18 month · "Very important" or "Extremely important"	31 Participants
Change in Perceived Benefits to Attend School: Important to Health 18 month · "Not at all important", "A little important", or "Somewhat important"	8 Participants
Change in Perceived Benefits to Attend School: Important to Health 21 month · "Very important" or "Extremely important"	32 Participants
Change in Perceived Benefits to Attend School: Important to Health 21 month · "Not at all important", "A little important", or "Somewhat important"	10 Participants
Change in Perceived Benefits to Attend School: Important to Health 24 month · "Very important" or "Extremely important"	29 Participants
Change in Perceived Benefits to Attend School: Important to Health 24 month · "Not at all important", "A little important", or "Somewhat important"	15 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, and impact on family. Survey will be analyzed qualitatively. * Compared to fully virtual school, how much better or worse is attending any school in-person for your child? * Dichotomized into: ("Quite a bit worse", "Somewhat worse", "A little bit worse", "Neither better nor worse") vs. ("A little bit better", "Somewhat better", "Quite a bit better")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Perceived Benefits to Attend School: In-person Schooling Baseline · "A little bit better", "Somewhat better", or "Quite a bit better"	35 Participants
Change in Perceived Benefits to Attend School: In-person Schooling Baseline · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	15 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 3 month · "A little bit better", "Somewhat better", or "Quite a bit better"	33 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 3 month · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	15 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 6 month · "A little bit better", "Somewhat better", or "Quite a bit better"	32 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 6 month · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	14 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 9 month · "A little bit better", "Somewhat better", or "Quite a bit better"	35 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 9 month · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	10 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 15 month · "A little bit better", "Somewhat better", or "Quite a bit better"	32 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 15 month · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	7 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 18 month · "A little bit better", "Somewhat better", or "Quite a bit better"	29 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 18 month · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	10 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 21 month · "A little bit better", "Somewhat better", or "Quite a bit better"	37 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 21 month · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	6 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 24 month · "A little bit better", "Somewhat better", or "Quite a bit better"	36 Participants
Change in Perceived Benefits to Attend School: In-person Schooling 24 month · "Quite a bit worse", "Somewhat worse", "A little bit worse", or "Neither better nor worse"	9 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively. * How much of your child's therapy needs are only met by attending school in-person? * Dichotomized into: ("None", "A few", "Some" vs. "Most", "All")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Perceived Benefits to Attend School: Therapy Needs Baseline · "Most", "All"	38 Participants
Change in Perceived Benefits to Attend School: Therapy Needs Baseline · "None", "A few", "Some"	13 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 3 month · "Most", "All"	32 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 3 month · "None", "A few", "Some"	16 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 6 month · "Most", "All"	33 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 6 month · "None", "A few", "Some"	13 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 9 month · "Most", "All"	31 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 9 month · "None", "A few", "Some"	14 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 15 month · "Most", "All"	26 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 15 month · "None", "A few", "Some"	13 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 18 month · "Most", "All"	27 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 18 month · "None", "A few", "Some"	12 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 21 month · "Most", "All"	29 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 21 month · "None", "A few", "Some"	14 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 24 month · "Most", "All"	30 Participants
Change in Perceived Benefits to Attend School: Therapy Needs 24 month · "None", "A few", "Some"	15 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively. * How positive or negative is your child attending school in-person for...your family * Dichotomized into: ("Very negative", "Somewhat negative", "A little negative", "Neutral") vs. ("A little positive", "Somewhat positive", "Very positive")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Perceived Benefits to Attend School: Positive for Family Baseline · "A little positive", "Somewhat positive", or "Very positive"	37 Participants
Change in Perceived Benefits to Attend School: Positive for Family Baseline · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	13 Participants
Change in Perceived Benefits to Attend School: Positive for Family 3 month · "A little positive", "Somewhat positive", or "Very positive"	37 Participants
Change in Perceived Benefits to Attend School: Positive for Family 3 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	11 Participants
Change in Perceived Benefits to Attend School: Positive for Family 6 month · "A little positive", "Somewhat positive", or "Very positive"	38 Participants
Change in Perceived Benefits to Attend School: Positive for Family 6 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	8 Participants
Change in Perceived Benefits to Attend School: Positive for Family 9 month · "A little positive", "Somewhat positive", or "Very positive"	38 Participants
Change in Perceived Benefits to Attend School: Positive for Family 9 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	7 Participants
Change in Perceived Benefits to Attend School: Positive for Family 15 month · "A little positive", "Somewhat positive", or "Very positive"	31 Participants
Change in Perceived Benefits to Attend School: Positive for Family 15 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	8 Participants
Change in Perceived Benefits to Attend School: Positive for Family 18 month · "A little positive", "Somewhat positive", or "Very positive"	30 Participants
Change in Perceived Benefits to Attend School: Positive for Family 18 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	9 Participants
Change in Perceived Benefits to Attend School: Positive for Family 21 month · "A little positive", "Somewhat positive", or "Very positive"	36 Participants
Change in Perceived Benefits to Attend School: Positive for Family 21 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	7 Participants
Change in Perceived Benefits to Attend School: Positive for Family 24 month · "A little positive", "Somewhat positive", or "Very positive"	37 Participants
Change in Perceived Benefits to Attend School: Positive for Family 24 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	8 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively. * How positive or negative is your child attending school in-person for...the staff and teachers * Dichotomized into: ("Very negative", "Somewhat negative", "A little negative", "Neutral") vs. ("A little positive", "Somewhat positive", "Very positive")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Perceived Benefits to Attend School: Positive for Staff Baseline · "A little positive", "Somewhat positive", or "Very positive"	34 Participants
Change in Perceived Benefits to Attend School: Positive for Staff Baseline · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	16 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 3 month · "A little positive", "Somewhat positive", or "Very positive"	36 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 3 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	11 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 6 month · "A little positive", "Somewhat positive", or "Very positive"	32 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 6 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	14 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 9 month · "A little positive", "Somewhat positive", or "Very positive"	38 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 9 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	7 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 15 month · "A little positive", "Somewhat positive", or "Very positive"	28 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 15 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	11 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 18 month · "A little positive", "Somewhat positive", or "Very positive"	30 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 18 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	9 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 21 month · "A little positive", "Somewhat positive", or "Very positive"	36 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 21 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	7 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 24 month · "A little positive", "Somewhat positive", or "Very positive"	36 Participants
Change in Perceived Benefits to Attend School: Positive for Staff 24 month · "Very negative", "Somewhat negative", or "A little negative", "Neutral"	9 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Parent survey perceived benefits construct survey will be having 6 questions ranging from benefits to child's overall health, therapy needs, impact on family. Survey will be analyzed qualitatively. * Does your child attending school in-person help the adults in your family to keep their jobs? * Response options: Yes / No

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Perceived Benefits to Attend School: Keep Jobs 21 month · Yes	29 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 21 month · No	14 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 24 month · Yes	28 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 24 month · No	17 Participants
Change in Perceived Benefits to Attend School: Keep Jobs Baseline · Yes	32 Participants
Change in Perceived Benefits to Attend School: Keep Jobs Baseline · No	19 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 3 month · Yes	29 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 3 month · No	19 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 6 month · Yes	26 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 6 month · No	20 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 9 month · Yes	24 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 9 month · No	21 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 15 month · Yes	22 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 15 month · No	17 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 18 month · Yes	25 Participants
Change in Perceived Benefits to Attend School: Keep Jobs 18 month · No	14 Participants

PRIMARY outcome

Timeframe: baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely \[comfortable\] vs not. * How comfortable are you with the number of people around your child at school? * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Number of People Baseline · "Very" or "Extremely" comfortable	21 Participants
Change in Barriers to School Attendance: Number of People Baseline · "Not at all", "A little", or "Somewhat" comfortable	30 Participants
Change in Barriers to School Attendance: Number of People 3 month · "Very" or "Extremely" comfortable	14 Participants
Change in Barriers to School Attendance: Number of People 3 month · "Not at all", "A little", or "Somewhat" comfortable	34 Participants
Change in Barriers to School Attendance: Number of People 6 month · "Very" or "Extremely" comfortable	17 Participants
Change in Barriers to School Attendance: Number of People 6 month · "Not at all", "A little", or "Somewhat" comfortable	29 Participants
Change in Barriers to School Attendance: Number of People 9 month · "Very" or "Extremely" comfortable	19 Participants
Change in Barriers to School Attendance: Number of People 9 month · "Not at all", "A little", or "Somewhat" comfortable	26 Participants
Change in Barriers to School Attendance: Number of People 15 month · "Very" or "Extremely" comfortable	12 Participants
Change in Barriers to School Attendance: Number of People 15 month · "Not at all", "A little", or "Somewhat" comfortable	27 Participants
Change in Barriers to School Attendance: Number of People 18 month · "Very" or "Extremely" comfortable	14 Participants
Change in Barriers to School Attendance: Number of People 18 month · "Not at all", "A little", or "Somewhat" comfortable	25 Participants
Change in Barriers to School Attendance: Number of People 21 month · "Very" or "Extremely" comfortable	13 Participants
Change in Barriers to School Attendance: Number of People 21 month · "Not at all", "A little", or "Somewhat" comfortable	30 Participants
Change in Barriers to School Attendance: Number of People 24 month · "Very" or "Extremely" comfortable	15 Participants
Change in Barriers to School Attendance: Number of People 24 month · "Not at all", "A little", or "Somewhat" comfortable	30 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely \[comfortable\] vs not. * How comfortable are you with how close people have to be to your child at school? * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Proximity Baseline · "Very" or "Extremely" comfortable	18 Participants
Change in Barriers to School Attendance: Proximity Baseline · "Not at all", "A little", or "Somewhat" comfortable	32 Participants
Change in Barriers to School Attendance: Proximity 3 month · "Very" or "Extremely" comfortable	12 Participants
Change in Barriers to School Attendance: Proximity 3 month · "Not at all", "A little", or "Somewhat" comfortable	36 Participants
Change in Barriers to School Attendance: Proximity 6 month · "Very" or "Extremely" comfortable	18 Participants
Change in Barriers to School Attendance: Proximity 6 month · "Not at all", "A little", or "Somewhat" comfortable	28 Participants
Change in Barriers to School Attendance: Proximity 9 month · "Very" or "Extremely" comfortable	17 Participants
Change in Barriers to School Attendance: Proximity 9 month · "Not at all", "A little", or "Somewhat" comfortable	28 Participants
Change in Barriers to School Attendance: Proximity 15 month · "Very" or "Extremely" comfortable	11 Participants
Change in Barriers to School Attendance: Proximity 15 month · "Not at all", "A little", or "Somewhat" comfortable	28 Participants
Change in Barriers to School Attendance: Proximity 18 month · "Very" or "Extremely" comfortable	13 Participants
Change in Barriers to School Attendance: Proximity 18 month · "Not at all", "A little", or "Somewhat" comfortable	26 Participants
Change in Barriers to School Attendance: Proximity 21 month · "Very" or "Extremely" comfortable	12 Participants
Change in Barriers to School Attendance: Proximity 21 month · "Not at all", "A little", or "Somewhat" comfortable	31 Participants
Change in Barriers to School Attendance: Proximity 24 month · "Very" or "Extremely" comfortable	18 Participants
Change in Barriers to School Attendance: Proximity 24 month · "Not at all", "A little", or "Somewhat" comfortable	27 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely \[comfortable\] vs not. * How comfortable are you with the amount personal protective equipment (PPE), such as masks and gloves, available at school? * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: PPE Baseline · "Very" or "Extremely" comfortable	24 Participants
Change in Barriers to School Attendance: PPE Baseline · "Not at all", "A little", or "Somewhat" comfortable	27 Participants
Change in Barriers to School Attendance: PPE 3 month · "Very" or "Extremely" comfortable	20 Participants
Change in Barriers to School Attendance: PPE 3 month · "Not at all", "A little", or "Somewhat" comfortable	28 Participants
Change in Barriers to School Attendance: PPE 6 month · "Very" or "Extremely" comfortable	25 Participants
Change in Barriers to School Attendance: PPE 6 month · "Not at all", "A little", or "Somewhat" comfortable	21 Participants
Change in Barriers to School Attendance: PPE 9 month · "Very" or "Extremely" comfortable	20 Participants
Change in Barriers to School Attendance: PPE 9 month · "Not at all", "A little", or "Somewhat" comfortable	25 Participants
Change in Barriers to School Attendance: PPE 15 month · "Very" or "Extremely" comfortable	10 Participants
Change in Barriers to School Attendance: PPE 15 month · "Not at all", "A little", or "Somewhat" comfortable	29 Participants
Change in Barriers to School Attendance: PPE 18 month · "Very" or "Extremely" comfortable	21 Participants
Change in Barriers to School Attendance: PPE 18 month · "Not at all", "A little", or "Somewhat" comfortable	18 Participants
Change in Barriers to School Attendance: PPE 21 month · "Very" or "Extremely" comfortable	19 Participants
Change in Barriers to School Attendance: PPE 21 month · "Not at all", "A little", or "Somewhat" comfortable	24 Participants
Change in Barriers to School Attendance: PPE 24 month · "Very" or "Extremely" comfortable	21 Participants
Change in Barriers to School Attendance: PPE 24 month · "Not at all", "A little", or "Somewhat" comfortable	24 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely \[comfortable\] vs not. * How comfortable are you with the amount of COVID-19 testing among school staff and classmates? * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Testing Baseline · "Very" or "Extremely" comfortable	11 Participants
Change in Barriers to School Attendance: Testing Baseline · "Not at all", "A little", or "Somewhat" comfortable	40 Participants
Change in Barriers to School Attendance: Testing 3 month · "Very" or "Extremely" comfortable	14 Participants
Change in Barriers to School Attendance: Testing 3 month · "Not at all", "A little", or "Somewhat" comfortable	34 Participants
Change in Barriers to School Attendance: Testing 6 month · "Very" or "Extremely" comfortable	16 Participants
Change in Barriers to School Attendance: Testing 6 month · "Not at all", "A little", or "Somewhat" comfortable	29 Participants
Change in Barriers to School Attendance: Testing 9 month · "Very" or "Extremely" comfortable	18 Participants
Change in Barriers to School Attendance: Testing 9 month · "Not at all", "A little", or "Somewhat" comfortable	26 Participants
Change in Barriers to School Attendance: Testing 15 month · "Very" or "Extremely" comfortable	10 Participants
Change in Barriers to School Attendance: Testing 15 month · "Not at all", "A little", or "Somewhat" comfortable	29 Participants
Change in Barriers to School Attendance: Testing 18 month · "Very" or "Extremely" comfortable	13 Participants
Change in Barriers to School Attendance: Testing 18 month · "Not at all", "A little", or "Somewhat" comfortable	26 Participants
Change in Barriers to School Attendance: Testing 21 month · "Very" or "Extremely" comfortable	13 Participants
Change in Barriers to School Attendance: Testing 21 month · "Not at all", "A little", or "Somewhat" comfortable	30 Participants
Change in Barriers to School Attendance: Testing 24 month · "Very" or "Extremely" comfortable	15 Participants
Change in Barriers to School Attendance: Testing 24 month · "Not at all", "A little", or "Somewhat" comfortable	30 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely \[comfortable\] vs not. * How comfortable are you with how closely parents of classmates follow recommendations to keep your child safe? * Dichotomized into: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Following Recommendations Baseline · "Very" or "Extremely" comfortable	13 Participants
Change in Barriers to School Attendance: Following Recommendations Baseline · "Not at all", "A little", or "Somewhat" comfortable	38 Participants
Change in Barriers to School Attendance: Following Recommendations 3 month · "Very" or "Extremely" comfortable	15 Participants
Change in Barriers to School Attendance: Following Recommendations 6 month · "Not at all", "A little", or "Somewhat" comfortable	32 Participants
Change in Barriers to School Attendance: Following Recommendations 9 month · "Very" or "Extremely" comfortable	14 Participants
Change in Barriers to School Attendance: Following Recommendations 9 month · "Not at all", "A little", or "Somewhat" comfortable	31 Participants
Change in Barriers to School Attendance: Following Recommendations 15 month · "Very" or "Extremely" comfortable	9 Participants
Change in Barriers to School Attendance: Following Recommendations 15 month · "Not at all", "A little", or "Somewhat" comfortable	30 Participants
Change in Barriers to School Attendance: Following Recommendations 18 month · "Very" or "Extremely" comfortable	13 Participants
Change in Barriers to School Attendance: Following Recommendations 18 month · "Not at all", "A little", or "Somewhat" comfortable	26 Participants
Change in Barriers to School Attendance: Following Recommendations 21 month · "Very" or "Extremely" comfortable	11 Participants
Change in Barriers to School Attendance: Following Recommendations 21 month · "Not at all", "A little", or "Somewhat" comfortable	32 Participants
Change in Barriers to School Attendance: Following Recommendations 24 month · "Very" or "Extremely" comfortable	14 Participants
Change in Barriers to School Attendance: Following Recommendations 24 month · "Not at all", "A little", or "Somewhat" comfortable	31 Participants
Change in Barriers to School Attendance: Following Recommendations 3 month · "Not at all", "A little", or "Somewhat" comfortable	33 Participants
Change in Barriers to School Attendance: Following Recommendations 6 month · "Very" or "Extremely" comfortable	14 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely vs not. * How difficult is it to transport your child to or from school as a result of COVID-19? * Dichotomized as: ("Not at all", "A little", "Somewhat") vs. ("Very", "Extremely")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Transportation Baseline · "Very" or "Extremely" difficult	5 Participants
Change in Barriers to School Attendance: Transportation Baseline · "Not at all", "A little", or "Somewhat" difficult	46 Participants
Change in Barriers to School Attendance: Transportation 3 month · "Very" or "Extremely" difficult	1 Participants
Change in Barriers to School Attendance: Transportation 3 month · "Not at all", "A little", or "Somewhat" difficult	47 Participants
Change in Barriers to School Attendance: Transportation 6 month · "Very" or "Extremely" difficult	3 Participants
Change in Barriers to School Attendance: Transportation 6 month · "Not at all", "A little", or "Somewhat" difficult	43 Participants
Change in Barriers to School Attendance: Transportation 9 month · "Very" or "Extremely" difficult	4 Participants
Change in Barriers to School Attendance: Transportation 9 month · "Not at all", "A little", or "Somewhat" difficult	41 Participants
Change in Barriers to School Attendance: Transportation 15 month · "Not at all", "A little", or "Somewhat" difficult	35 Participants
Change in Barriers to School Attendance: Transportation 18 month · "Very" or "Extremely" difficult	2 Participants
Change in Barriers to School Attendance: Transportation 18 month · "Not at all", "A little", or "Somewhat" difficult	35 Participants
Change in Barriers to School Attendance: Transportation 21 month · "Very" or "Extremely" difficult	2 Participants
Change in Barriers to School Attendance: Transportation 21 month · "Not at all", "A little", or "Somewhat" difficult	41 Participants
Change in Barriers to School Attendance: Transportation 24 month · "Very" or "Extremely" difficult	1 Participants
Change in Barriers to School Attendance: Transportation 24 month · "Not at all", "A little", or "Somewhat" difficult	44 Participants
Change in Barriers to School Attendance: Transportation 15 month · "Very" or "Extremely" difficult	4 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely vs not. * In your child's school, do they have access to necessary facilities to wash? * Dichotomized as: ("Yes, all of the time", "Yes, most of the time") vs. ("Some of the time", "Rarely", "Not at all")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Wash Baseline · "Yes, all of the time" or "Yes, most of the time"	43 Participants
Change in Barriers to School Attendance: Wash Baseline · "Some of the time", "Rarely", or "Not at all"	8 Participants
Change in Barriers to School Attendance: Wash 3 month · "Yes, all of the time" or "Yes, most of the time"	45 Participants
Change in Barriers to School Attendance: Wash 3 month · "Some of the time", "Rarely", or "Not at all"	3 Participants
Change in Barriers to School Attendance: Wash 6 month · "Yes, all of the time" or "Yes, most of the time"	41 Participants
Change in Barriers to School Attendance: Wash 6 month · "Some of the time", "Rarely", or "Not at all"	5 Participants
Change in Barriers to School Attendance: Wash 9 month · "Yes, all of the time" or "Yes, most of the time"	40 Participants
Change in Barriers to School Attendance: Wash 9 month · "Some of the time", "Rarely", or "Not at all"	5 Participants
Change in Barriers to School Attendance: Wash 15 month · "Yes, all of the time" or "Yes, most of the time"	33 Participants
Change in Barriers to School Attendance: Wash 15 month · "Some of the time", "Rarely", or "Not at all"	6 Participants
Change in Barriers to School Attendance: Wash 18 month · "Yes, all of the time" or "Yes, most of the time"	32 Participants
Change in Barriers to School Attendance: Wash 18 month · "Some of the time", "Rarely", or "Not at all"	7 Participants
Change in Barriers to School Attendance: Wash 21 month · "Yes, all of the time" or "Yes, most of the time"	37 Participants
Change in Barriers to School Attendance: Wash 21 month · "Some of the time", "Rarely", or "Not at all"	6 Participants
Change in Barriers to School Attendance: Wash 24 month · "Yes, all of the time" or "Yes, most of the time"	39 Participants
Change in Barriers to School Attendance: Wash 24 month · "Some of the time", "Rarely", or "Not at all"	6 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely \[comfortable\] vs not. * While in school, is your child required to be in close contact (i.e., within 6 ft) with others? 'Others' includes teachers, aides, nurses, and classmates. * Dichotomized as: ("Yes, all of the time", "Yes, most of the time") vs. ("Some of the time", "Rarely", "Not at all")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Close Contact Baseline · "Yes, all of the time" or "Yes, most of the time"	47 Participants
Change in Barriers to School Attendance: Close Contact Baseline · "Some of the time", "Rarely", or "Not at all"	4 Participants
Change in Barriers to School Attendance: Close Contact 3 month · "Yes, all of the time" or "Yes, most of the time"	42 Participants
Change in Barriers to School Attendance: Close Contact 3 month · "Some of the time", "Rarely", or "Not at all"	6 Participants
Change in Barriers to School Attendance: Close Contact 6 month · "Yes, all of the time" or "Yes, most of the time"	41 Participants
Change in Barriers to School Attendance: Close Contact 6 month · "Some of the time", "Rarely", or "Not at all"	5 Participants
Change in Barriers to School Attendance: Close Contact 9 month · "Yes, all of the time" or "Yes, most of the time"	44 Participants
Change in Barriers to School Attendance: Close Contact 9 month · "Some of the time", "Rarely", or "Not at all"	1 Participants
Change in Barriers to School Attendance: Close Contact 15 month · "Yes, all of the time" or "Yes, most of the time"	36 Participants
Change in Barriers to School Attendance: Close Contact 15 month · "Some of the time", "Rarely", or "Not at all"	3 Participants
Change in Barriers to School Attendance: Close Contact 18 month · "Yes, all of the time" or "Yes, most of the time"	36 Participants
Change in Barriers to School Attendance: Close Contact 18 month · "Some of the time", "Rarely", or "Not at all"	3 Participants
Change in Barriers to School Attendance: Close Contact 21 month · "Yes, all of the time" or "Yes, most of the time"	40 Participants
Change in Barriers to School Attendance: Close Contact 21 month · "Some of the time", "Rarely", or "Not at all"	3 Participants
Change in Barriers to School Attendance: Close Contact 24 month · "Yes, all of the time" or "Yes, most of the time"	43 Participants
Change in Barriers to School Attendance: Close Contact 24 month · "Some of the time", "Rarely", or "Not at all"	1 Participants

PRIMARY outcome

Timeframe: Baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Survey will have following questions which will be answered dichotomously very/extremely vs not. * While in school, is your child able to wear a mask? * Dichotomized as: ("Yes, all of the time", "Yes, most of the time") vs. ("Some of the time", "Rarely", "Not at all")

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Barriers to School Attendance: Masking Baseline · "Yes, all of the time" or "Yes, most of the time"	24 Participants
Change in Barriers to School Attendance: Masking Baseline · "Some of the time", "Rarely", or "Not at all"	27 Participants
Change in Barriers to School Attendance: Masking 3 month · "Yes, all of the time" or "Yes, most of the time"	23 Participants
Change in Barriers to School Attendance: Masking 3 month · "Some of the time", "Rarely", or "Not at all"	25 Participants
Change in Barriers to School Attendance: Masking 6 month · "Yes, all of the time" or "Yes, most of the time"	21 Participants
Change in Barriers to School Attendance: Masking 6 month · "Some of the time", "Rarely", or "Not at all"	25 Participants
Change in Barriers to School Attendance: Masking 9 month · "Yes, all of the time" or "Yes, most of the time"	19 Participants
Change in Barriers to School Attendance: Masking 9 month · "Some of the time", "Rarely", or "Not at all"	26 Participants
Change in Barriers to School Attendance: Masking 15 month · "Yes, all of the time" or "Yes, most of the time"	18 Participants
Change in Barriers to School Attendance: Masking 15 month · "Some of the time", "Rarely", or "Not at all"	21 Participants
Change in Barriers to School Attendance: Masking 18 month · "Yes, all of the time" or "Yes, most of the time"	16 Participants
Change in Barriers to School Attendance: Masking 18 month · "Some of the time", "Rarely", or "Not at all"	23 Participants
Change in Barriers to School Attendance: Masking 21 month · "Yes, all of the time" or "Yes, most of the time"	14 Participants
Change in Barriers to School Attendance: Masking 21 month · "Some of the time", "Rarely", or "Not at all"	29 Participants
Change in Barriers to School Attendance: Masking 24 month · "Yes, all of the time" or "Yes, most of the time"	16 Participants
Change in Barriers to School Attendance: Masking 24 month · "Some of the time", "Rarely", or "Not at all"	28 Participants

PRIMARY outcome

Timeframe: baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Participants will answer the following survey question in Yes/No: * "Teachers/staff have asked for my child to attend school."- Y/N

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 15-month · No	14 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 18-month · Yes	30 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 18-month · No	9 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) Baseline · Yes	29 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) Baseline · No	22 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 3-month · Yes	31 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 3-month · No	17 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 6-month · Yes	34 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 6-month · No	12 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 9-month · Yes	32 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 9-month · No	13 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 15-month · Yes	25 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 21-month · Yes	33 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 21-month · No	10 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 24-month · Yes	36 Participants
Change in Cues: Has a Teacher or Staff Member Encouraged Child to Attend School In-person? (Y/N) 24-month · No	8 Participants

PRIMARY outcome

Timeframe: baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Participant will be asked the attendance question in survey. It will be answered in Yes/No

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N Baseline · Yes	29 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N Baseline · No	22 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 3-month · Yes	35 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 3-month · No	13 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 6-month · Yes	35 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 6-month · No	11 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 9-month · Yes	37 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 9-month · No	8 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 15-month · Yes	32 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 15-month · No	7 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 18-month · Yes	33 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 18-month · No	6 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 21-month · Yes	37 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 21-month · No	6 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 24-month · Yes	38 Participants
Change in Option and Practice: Currently, is Child Attending School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 24-month · No	7 Participants

PRIMARY outcome

Timeframe: baseline, 3 month, 6 month, 9-12 month, 15 month, 18 month, 21 month, 24 month

Population: The number analyzed varies per row due to varied response rates per question at each time point.

Participant will be asked the attendance question in survey. It will be answered in Yes/No. Survey branching logic asked this question only to participants whose child was not currently attending school in person, either full-time or as part of a hybrid or part-time schedule. The number analyzed represents the number of participants that answered this question.

Outcome measures

Outcome measures
Measure	Caregiver of Children With Medical Complexity (CMC) n=51 Participants BinaxNOW Rapid Antigen System: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes. The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N Baseline · Yes	14 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N Baseline · No	8 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 3-month · Yes	9 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 3-month · No	4 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 6-month · Yes	8 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 6-month · No	3 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 9-month · Yes	7 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 9-month · No	1 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 15-month · Yes	4 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 15-month · No	3 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 18-month · Yes	3 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 18-month · No	3 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 21-month · Yes	4 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 21-month · No	2 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 24-month · Yes	4 Participants
Change in Option and Practice: Currently, if Participant Wanted, Could the Child Attend School In-person, Either Full-time or as Part of a Hybrid or Part-time Schedule? Y/N 24-month · No	3 Participants

Adverse Events

Children With Medical Complexity (CMC)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 1 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Ryan Coller

University of Wisconsin School of Medicine and Public Health

Phone: 608-263-9408

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place